text: Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021 | Biotech 365	
  Skip to primary content
  Biotech 365
  Search
  Main menu
  Biotech 365
  BioLeads – Find new scientific customers
  Healthcare Investors
  Scientists and Researchers Database
  Post navigation
  ← Previous Next →
  Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
  Posted on by
  Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
  Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
  BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) — Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021. Athenex’s management team will host a conference call and live audio webcast at 10:00 a.m. Eastern Time.
  To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:
  Domestic: (855) 227-0567
  International: (612) 979-9912
  Passcode: 7292300
  The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.
  About Athenex, Inc.
  Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell therapy, and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.
  Athenex Contacts
  Investors
  Daniel Lang, MD
  Athenex, Inc.
  Email: danlang@athenex.com
  Caileigh Dougherty
  Athenex, Inc.
  Email: cdougherty@athenex.com
  This entry was posted in GlobeNewswire by . Bookmark the permalink.
  Do you need to raise your next Funding round? In-Licensing / Out-Licensing of your assets? Distribution / Commercialization of your products? Want to create a spin-off with your IP?
  Contact us!
  Search
  Do you need a specific database in Healthcare (researchers, Biotech/Pharma companies, CRO/CDMO, etc.)?
  Contact us!
  Contact Offers - Services - Licensing - Funding Healthcare Venture Building Biotech Jobs Biotech & Pharma News